Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On July 13, 2010 the Company announced the formation of its first subsidiary, Neuro-Biotech Lab Canada Inc., having its offices at 1002 Sherbrooke Street West, 28E Floor, Montréal QC, H3A 3L6, Canada. The main purpose of the Canadian subsidiary is to establish the Ne uro-Biotech main laboratory in Technoparc Montreal ( www.technoparc.com ) near the Montreal International Airport , where Research and Development are to be conducted, along with the analysis of various medical diagnostic tests were the results will be made available to the medical community.
love it !!! cant be more concrete than that...
IT S FOR THE LICENSES!!!! HAVEN T YOU READ IT ???
CHEAZZ...
As consideration for the above-mentioned 16 licenses, the Company issued 615,000,000, in the aggregate, shares of Common Stock, whereby 315,000,000 shares of Common Stock were issued to Squib & Waves Research Inc. and 300,000,000 shares of Common Stock were issued to Northern Carrabean Star Inc. Squib & Waves Research Inc. and Northern Carrabean Star Inc. have agreed to invest the sum of 2,000,000 USD in Neuro-Biotech Corp. within fifteen (15) months from the date of April 30, 2010, as a direct and proximate result of the above-styled license agreements.
STOP WITH THE GOSSIP!!!
MORE GOOD NEWZ !!!
HE-5's Significant Source of Income: Triple Crown CRM Hunter Suite, Customizable Version for Select Members With Unique Needs
HE-5 RES CORP (OTC) (USOTC:HRRN)
Intraday Stock Chart
Today : Wednesday 11 August 2010
Click Here for more HE-5 RES CORP (OTC) Charts.
HE-5 Resources Corp. (Other OTC: HRRN.PK) wishes to inform its shareholders about one of its major sources of income: The Hunter Suite. This fully customizable version of the Triple Crown CRM is available for businesses and individuals alike, who have specific software requirements. This special version of the HE-5 Software Suite can be fully adapted for the customers' activities and needs. The Hunter Suite gives users access to software modules and Triple Crown CRM software options that are not yet available to the general public. Moreover, most of the present and future software enhancements (in the Mustang Suite for example) were designed primarily for clients using the Hunter Suite. Subsequently, they were then adapted for the other CRM (Customer Relationship Management) versions.
This suite has been available as of the launch of Mustang-Look, thereby meeting the needs for CRM, ERP (Enterprise Resource Planning) and CMS (Content Management System) applications of several private companies situated around the world. HE-5 Resources is proud to provide these companies a cost efficient and revenue enhancing way to further their goals.
Triple Crown CRM: A ride together to a flourishing future.
8-K OUT
- Current report filing (8-K)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 10, 2010
Neuro – Biotech Corp.
(Exact Name of Registrant as Specified in Charter)
Nevada
33-55254-42
87-0485310
(State or Other Jurisdiction
(Commission
(IRS Employer
of Incorporation)
File Number)
Identification No.)
Aeschenvorstadt 71, CH-4051 Basel, Switzerland
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: 41 61 500 05 16
M45 Mining Resources, Inc., 4020 St-Ambroise, Suite 497, Montreal, Quebec Canada
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 4.01 Changes in Registrant’s Certifying Accountant.
(a)
(1) Previous Independent Accountant
(i)
On July 26, 2010 the Registrant changed its independent auditor, Patrick Rodgers, CPA, PA (“Rodgers”).
(ii)
The reports of Rodgers as of and for the fiscal years ended March 31, 2008 and 2009, did not contain any adverse opinion or disclaimer of opinion, or were qualified or modified as to uncertainty, audit scope or accounting principles.
(iii)
The Board of Directors agreed to change the Registrant’s independent auditor.
(iv)
During the fiscal years ended March 31, 2008 and 2009 and any subsequent interim period preceding such departure of Rodgers, there were no disagreements with Rodgers on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure.
(v)
Rodgers has not advised the Registrant of any events described in paragraphs (A) through (D) of Regulation S-K Item 304(a)(1)(v).
(2) New Independent Accountant
The Registrant engaged Michael Pollack, CPA of KBP, LLP as its independent auditor to provide the requisite audit services for the Registrant. KBL, LLP commenced its engagement effective July 22, 2010 as requested and approved by the Registrant’s Board of Directors. The Registrant did not consult with KBP, LLP on any matter at any time prior to the engagement.
(3) Please see the attached letter from Patrick Rodgers, CPA, PA regarding his review of the abovementioned disclosure made in response to this Item 304(a).
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On February 26, 2010 the Company and its stockholders deemed it to be in the best interest of the Company that Article THIRD of the Company’s Articles of Incorporation be stricken in its entirety and replaced as follows:
THIRD : Authorized Stock: The total number of Shares which the Company shall have authority to issue is One Billion (1,000,000,000) Common Shares, with a par value of $0.001 per share.
Prior to such amendment, the Company had authority to issue Three Hundred Million (300,000,000) Common Shares, with a par value of $0.001 per share.
Item 9.01 Financial Statements and Exhibits.
Letter from the previous independent accountant, Patrick Rodgers, CPA, PA
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
Date: August 10, 2010
NEURO-BIOTECH CORP.
/s/ Barry Somervail
Barry Somervail, Chief Executive Officer
HAHA and right back up and more...
with a transaction of 300$ lol ...
yup indeed, cant wait for the west coast to open...
GOOD REACTION FROM THE MARKET,
10:30 and already 3 000 000 Volume, not bad...
AND I AM SOOOOOOOOOOOOOOOOOO RIGHTM IT WENT UPPPP !!!!!!
PFFFF
The fact that there is 1.8 billion of outstanding shares have NOTHING TO DO with the decreasing PPS , NNOOTTHHIINNGG !!!!
No relation AT ALL between the 2...
LOLOL
Yea i know, that is big indeed....
FINANCIAL OUT ''PROFIT''
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=34521
LOOKING GOOD !!!!
Like i just said, DONT CARE.. it s all about the volume for now....
for me it s a good way to end the week...
We dont care about about the PPS or your whatever ''paint job'', we care about he VOLUME.. HE WAS TALKING ABOUT THE VOLUME,...
that s what was important today!!!
pfff
oh cheese.. i really have to explain you everything ( and do everything for you) the important one is first the license and second the foreign patent that cover all of it and all of them ...
...
I really have to do EVERYTHING for you hein!!!
US PATENT NUMBER: 5,879,902
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=3&f=G&l=50&d=PTXT&S1=5,879,902&OS=5,879,902&RS=5,879,902
LICENSE FROM HEALTH CANADA NUMBER: 2558
INTERNATIONAL PATENT PCT NUMBER : WO90/58076
Do I have to put them all can you take it from here and do the rest your self???
LOLOL
normal, it s UNDER CONSTRUCTION...
HAHA
What are you not understanding in the phrase '' THIS SITE IS UNDER CONSTRUCTION'' ???
pfff. LOL
well, i can t say it s the time to buy, but i can tell you that i am buying everything i can...
OK, oops, its FINRA that does it,
but yea kid, keep concentrating on useless detail instead of admitting your were wrong all the way about NEURO-BIOTECH, now you have patent and TM to make your DD on and the only thing you do is only focusing on a little swap betwin SEC and FINRA ...
LOLOL
MRES is now a GOLD MINE, no R&D to finance, just selling some really needed product that are already in HIGHT demand all over the world !!!
STOP WITH YOUR SEC, IT S FINRA THAT DOES THAT....
LOLOL
Go check the product and the trade mark at least, dont be that lazy..
and what other PR, IT S THE FISRT
HAHA
7000 volume, that s a market maker...pfff
LOLOLOL
As I said, NEURO-BIOTECH IS A GOLD NUGGET!!!!
look the news... and to you research on the patent and Trade Mark !!!
NEWZ OUT!LOOKING VERY GREAT!
Neuro-Biotech Corp. - Update to Shareholders
Neuro-Biotech Corp. Common Stock (USOTC:MRES)
Intraday Stock Chart
Today : Tuesday 27 July 2010
Click Here for more Neuro-Biotech Corp. Common Stock Charts.
Neuro-Biotech Corp. (PINKSHEETS: MRES) (OTCQB: MRES) provides update to shareholders.
As most of you have already noted that major changes have been taking place in the past months, the most noticeable one being the change of our company's orientations. All those changes have been done with the best interest of all ordinary share holders having in mind to create a tangible value to all. With this as a priority, the board has decided to cancel all previous contracts and agreements in the mining sector as well as all other related transactions. In initiating such a mutual agreement between the board signatories and all concerned parties, all issued shares for this and all other related transactions were returned to the treasury of the company for cancellation.
The new Board of Directors and management team being formed and nominated will consist of professionals working in the scientific and medical communities. Until this process is finalized, members of the old board have remained in order to make this transition as seamless as possible. The new CEO, being a medical doctor, will assume his functions in the next 30 days.
On or about April 30, 2010, the Company signed 16 worldwide license agreements exclusively for the manufacturing and distribution of two groups of products. First, an innovative portfolio of quantitative "in vitro" diagnostic kits which offer easy detection of various molecules released within the blood for subjects suffering of stress and neuroscience -- related disorders. Second, natural brain adaptogene products -- called Neuroceuticals™, specifically designed to stimulate targeted neurotransmitters and provide health benefit effects, are ready to be introduced to the market. Details concerning these highly specialized products and all relevant scientific documentation will be published on the corporate website (http://neuro-biotechcorp.com). In the coming weeks, this site will be accessible in stages to shareholders, thereafter to the general public and finally, the section for the scientific community will be available at the end of the summer.
One of the most noticeable differences between us and the other companies working in the field of Nanotechnology and Biotechnology is that we don't need to finance any further R&D (research and development), as this process has been completed during the past 30 years and our products have been tested according to standardized protocols in this domain. Therefore, R&D has been completed and the products are ready to be brought to the market. Some are already in the process of being ordered and negotiations are currently underway with several interested parties in various countries.
It was therefore urgent to form the Canadian subsidiary in order to open our laboratory within Good Laboratory Practice guidelines and our distribution center as quickly as possible to fulfill these orders in hand. Our laboratory will be recognized as a CRO (clinical research organization) in order to offer our R&D expertise on a contract basis for clinical studies in the field of neuroscience. Other foreign subsidiaries are currently under negotiation, but their purpose is commercial in nature in order to distribute our products according to the standards of each individual country.
Our corporation headquarters is based in Basel, Switzerland, closer to our target market, the "Big Pharma." Initially, this office will be available in its simplest form, but will contain the necessary facilities for various professional groups to hold meetings and negotiations.
As will be realized, with the opening of different sections of the company's website, and the information that becomes available, our corporate activities will be sharply focused in Diagnostic methods and kits for the evaluation of the sympathetic nervous system function. In order to respond appropriately and responsively, we are currently negotiating with IR firms specializing in these areas.
We also wish to inform our shareholders that a first attempt was launched a few years ago to market one of the tests. This first commercialization effort was neither a success nor a failure, for the following reasons: Firstly, the investment vehicle chosen, the Vancouver stock exchange, was too locally focused, while being situated in a country (Canada) which originally denied the existence of mental illnesses, by its absence at the International Commission on mental illness of the WHO (World Health Organization). Secondly, they did not meet the company's business opportunity objectives, which created deep divisions within the ownership group, leading to the researchers' decision to withdraw.
It should also be mentioned that these tests were so revolutionary just a few years ago, that they created a similar public reaction and controversy as "stem cell research". Individuals were afraid that with a single drop of blood, they could be negatively identified, and that medical institutions could monitor a wide range of neuroscience and stress related disorders of the brain.
Today, in the present environment, society more than welcomes all early diagnostic testing measuring the input and output of the brain to detect any early stage of potential degeneration in the brain (ex: Alzheimer's disease), as well as early detection of PTSD (Post Traumatic Stress Disorder), which was not the case 5 years ago.
As mentioned previously, the website of the corporation will answer most questions on our products. It will also explain to health professionals via scientific documentation. Until we engage the services of a specialized IR firm, please forward all requests and questions by info@neuro-agora.com. The appropriate person will follow-up.
Forward Looking Statements
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance
may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
Contact:
Neuro-Biotech Corp.
info@neuro-agora.com
Every Body just need to wait a bit more on this one, and we will know a lot more..
OK so thank you for proving me right, you haven t talk to the SEC nor to FINRA about NEURO, so thanks for admitting out loud that you dont know nothing about NEURO or their Fillings ... or even their product..
sometime honesty is so much better and simple isnt it ???
LOLOL
WRONG... they have, and they do.. specially when they classified a company to OTCQX...
like i said before, you havent talk to them about that.. nor you talk to NEURO so YOU DONT KNOW ...
thank you !!!!
HAHA pff how can you say that ??? have you talked to them NO !!! so you dont know, THEY DID !!!
LOLOL
sorry but YOU ARE WRONG , and know nothing about that or NEURO-BIOTECH!!
LOOOL
TO BECOME OTCQX YES!!!!!
WRONG, to do a name change you have to send all the files of the company since the beginning to the SEC , then they will analyze and verified it before giving the OK, especially if we are talking about a OTCQX US Register Company...
pfff!!!
pff..ok you wanna play the English teacher, i forgot a '','' after the word ''audited'' cuz is the financial statements the Qs and the Ks that are 100% audited, and the company that is verified by the SEC !!!
Happy now???
LOLOLOL
ok so what is -21%, 25 000 volume, 45$ ???
A Reverse Tape Painting ???
LOLOL
you are talking about M45 here, not NEURO-BIOTECH!!! A fully Reporting OTCQX 100% audited and verified by the SEC...
call them if you have complain to do
LOLOL
as long as i am cashing in ... no problem for me LOLOL
Volume is building back, slowly but still 4 times the 10 day average.. not bad
OOPS lill bug on my side sorry , your right... at least there was volume lolol
let see tomorow
so what ??? what do we care about if he went bankrupted ???
Same here, this one will blow, everything is there so it..
let see what the rest of the week will be !!!
Has long as they reinvest the money they are suppose to, there is no evil on my side !
In my opinion they are groups of private investors like a edge fund or something, so it s normal not to find any traces of them on the Internet...